Description
Tradename:
Lustral
Compound:
Each tablet contains:
Sertraline hydrochloride 50 mg.
Properties:
Sertraline is a selective serotonin reuptake inhibitor. It has a very weak effect on the reuptake of norepinephrine and dopamine. It does not have a specific affinity for adrenergic and m-cholinergic receptors, GABA receptors, dopamine, histamine, serotonin or benzodiazepine receptors. Does not inhibit MAO. Causes anorexia, effective for obsessive states.
Indications:
Treatment of major depressive episodes. Prevention of relapse of major depressive episodes. Panic disorder with or without agoraphobia. Obsessive-compulsive disorder (OCD) in adults and children aged 6-17 years. Social anxiety disorder. Post-traumatic stress disorder (PTSD).
Directions for use and dosage:
Orally, the tablet should be taken 1 time per day, in the morning or evening, regardless of meals. Dosage during long-term therapy should be maintained at the lowest effective level with subsequent adjustments based on therapeutic response.
Initial treatment. Depression and OCD: should start with a dose of 50 mg/day. Panic disorder, PTSD and social anxiety: Initial dose is 25 mg/day. After a week, the dose should be increased to 50 mg once a day. This dose reduces the incidence of early manifestations that occur with side effects characteristic of panic disorder.
Continuation of therapy. Depression, OCD, panic disorder, social anxiety and PTSD. Patients not responding to the 50 mg dose may have their dose increased. Dose changes should be made in 50 mg increments at intervals of at least one week, up to a maximum of 200 mg/day.
The therapeutic effect can be observed within 7 days. Patients with depression should be treated for a sufficient period of time, at least 6 months, to ensure that they remain symptom-free. Continuity of treatment for panic disorder and OCD should be assessed regularly as relapse prevention is not indicated for these disorders.
Elderly people should dose carefully. In patients with liver disease, a lower or less frequent dose is used.
Children and adolescents with obsessive-compulsive disorder. From 13-17 years: initial dose – 50 mg 1 time per day. From 6-12 years: initial dose – 25 mg 1 time per day. The dosage can be increased to 50 mg 1 time per day after a week. Patients not responding to the 50 mg dose may have their dose increased. Dose changes should be made in 50 mg increments at intervals of several weeks, up to a maximum of 200 mg/day.
When discontinuing sertraline treatment, the dose should be gradually reduced over a period of 1 to 2 weeks to reduce the risk of adverse reactions. If intolerable symptoms occur after reducing the dose or stopping treatment, consult a doctor.
Contraindications:
Children under 6 years old; hypersensitivity to sertraline or any of the excipients. Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs). Concomitant use of pimozide. Pregnancy and lactation.
Precautionary measures:
Sertraline should be used with caution in patients with a history of mania/hypomania. Careful monitoring by a physician is required. Sertraline should be discontinued in any patient entering a manic phase. Psychotic symptoms may be exacerbated in patients with schizophrenia. Seizures may occur during sertraline therapy: sertraline should be avoided in patients with unstable epilepsy and patients with controlled epilepsy should be closely monitored. Symptoms of sexual dysfunction may occur. Sertraline should not be used in the treatment of children and adolescents under the age of 18 years, with the exception of patients with obsessive-compulsive disorder aged 6-17 years. Sertraline should not be administered within 14 days of stopping treatment with an irreversible MAOI. Sertraline should be discontinued for at least 7 days before starting treatment with an irreversible MAOI. Taking sertraline with grapefruit juice is not recommended.
Side effects:
Depends on the dose and is transient with continued treatment: nausea, sexual dysfunction. If you abruptly stop taking the drug: dizziness, sensory disturbances, sleep disturbances, agitation or restlessness, nausea and/or vomiting, tremor and headache.
Storage method:
Keep out of the reach of children.
